MX2023001726A - Anticuerpos anti-c5 y usos de los mismos. - Google Patents
Anticuerpos anti-c5 y usos de los mismos.Info
- Publication number
- MX2023001726A MX2023001726A MX2023001726A MX2023001726A MX2023001726A MX 2023001726 A MX2023001726 A MX 2023001726A MX 2023001726 A MX2023001726 A MX 2023001726A MX 2023001726 A MX2023001726 A MX 2023001726A MX 2023001726 A MX2023001726 A MX 2023001726A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- bind
- protein
- provides
- neutralizing
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales que se unen a la proteína del factor de complemento 5 (C5), y métodos de uso de los mismos. En diversas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a la proteína C5. En algunas realizaciones, los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad de C5, proporcionando así un medio para tratar o prevenir una enfermedad o trastorno relacionado con C5 en humanos. En algunas realizaciones, la invención proporciona un anticuerpo anti-C5 que tiene propiedades farmacocinéticas y farmacodinámicas mejoradas, por ejemplo, una vida media de más de 10 días.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662349705P | 2016-06-14 | 2016-06-14 | |
US201662405561P | 2016-10-07 | 2016-10-07 | |
US201662422107P | 2016-11-15 | 2016-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001726A true MX2023001726A (es) | 2023-02-22 |
Family
ID=59091673
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015149A MX2018015149A (es) | 2016-06-14 | 2017-06-13 | Anticuerpos anti-c5 y usos de los mismos. |
MX2023001726A MX2023001726A (es) | 2016-06-14 | 2018-12-06 | Anticuerpos anti-c5 y usos de los mismos. |
MX2023001727A MX2023001727A (es) | 2016-06-14 | 2018-12-06 | Anticuerpos anti-c5 y usos de los mismos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015149A MX2018015149A (es) | 2016-06-14 | 2017-06-13 | Anticuerpos anti-c5 y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001727A MX2023001727A (es) | 2016-06-14 | 2018-12-06 | Anticuerpos anti-c5 y usos de los mismos. |
Country Status (20)
Country | Link |
---|---|
US (4) | US10633434B2 (es) |
EP (2) | EP3468990B1 (es) |
JP (3) | JP7102353B2 (es) |
KR (3) | KR102534895B1 (es) |
CN (3) | CN116751293A (es) |
AU (1) | AU2017283470B2 (es) |
CA (1) | CA3027487A1 (es) |
CL (1) | CL2018003563A1 (es) |
CO (1) | CO2018014413A2 (es) |
DK (1) | DK3468990T3 (es) |
FI (1) | FI3468990T3 (es) |
IL (2) | IL309975A (es) |
LT (1) | LT3468990T (es) |
MA (1) | MA45235A (es) |
MX (3) | MX2018015149A (es) |
MY (3) | MY196220A (es) |
PH (1) | PH12018502560A1 (es) |
SG (2) | SG10202012243VA (es) |
UA (1) | UA124734C2 (es) |
WO (1) | WO2017218515A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
EP2815766B1 (en) * | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
LT3233921T (lt) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antikūnai ir panaudojimo būdai |
IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Antibodies against C5 and their uses |
JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Il−8関連疾患の治療用又は予防用組成物 |
IL269122B1 (en) * | 2017-03-06 | 2024-03-01 | Univ Pennsylvania | Antibodies against C5 and their uses |
EP4218813A3 (en) | 2017-07-27 | 2023-08-16 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
EP4116327A1 (en) | 2017-10-11 | 2023-01-11 | Board Of Regents, The University Of Texas System | Human pd-l1 antibodies and methods of use therefor |
CN111868081A (zh) * | 2017-10-26 | 2020-10-30 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
CA3092695A1 (en) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Human pd-l2 antibodies and methods of use therefor |
CN117586412A (zh) * | 2018-03-23 | 2024-02-23 | 得克萨斯州大学系统董事会 | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 |
CA3135166A1 (en) * | 2018-04-26 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for retrieving tumor-related antibodies and antigens |
EP3802593A1 (en) * | 2018-05-31 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
JP2021528957A (ja) | 2018-06-28 | 2021-10-28 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗c5抗体の産生方法 |
US20220056115A1 (en) * | 2018-09-17 | 2022-02-24 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
JP2022501378A (ja) | 2018-09-21 | 2022-01-06 | アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. | 視神経脊髄炎の処置のためのエクリズマブ |
WO2020092546A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
US20210395352A1 (en) | 2018-10-30 | 2021-12-23 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
CN113614105A (zh) | 2019-01-25 | 2021-11-05 | 亚力兄制药公司 | 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用 |
MX2021009789A (es) | 2019-02-14 | 2021-11-17 | Alexion Pharma Inc | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. |
WO2020242849A1 (en) | 2019-05-24 | 2020-12-03 | Alexion Pharmaceuticals, Inc. | Methods of treating vitiligo using an anti-c5 antibody |
US20220259305A1 (en) | 2019-08-05 | 2022-08-18 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
KR20220047826A (ko) * | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | 고 농도의 항-c5 제형 |
US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
EP4048691A1 (en) | 2019-10-25 | 2022-08-31 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for treating or preventing c5-associated diseases |
JP2023504209A (ja) | 2019-12-09 | 2023-02-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 視神経脊髄炎スペクトラム障害の治療のための抗c5抗体 |
US20230043576A1 (en) | 2019-12-23 | 2023-02-09 | Alexion Pharmaceuticals, Inc. | Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CN111234016B (zh) * | 2020-02-23 | 2021-09-07 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c5分子的全人源单克隆抗体及应用 |
BR112022021136A2 (pt) | 2020-04-30 | 2022-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas |
EP4149473A1 (en) | 2020-05-12 | 2023-03-22 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
US20230349887A1 (en) | 2020-05-15 | 2023-11-02 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
EP4171737A1 (en) | 2020-06-24 | 2023-05-03 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
US20230235035A1 (en) | 2020-07-09 | 2023-07-27 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
WO2022036151A1 (en) | 2020-08-13 | 2022-02-17 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2022060931A1 (en) | 2020-09-21 | 2022-03-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) |
EP4232473A1 (en) | 2020-10-23 | 2023-08-30 | Alexion Pharmaceuticals, Inc. | Methods of treating patients having complement disorders using anti-c5 antibodies |
US20240092881A1 (en) | 2021-01-22 | 2024-03-21 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
WO2022265915A1 (en) | 2021-06-14 | 2022-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) |
WO2023287991A1 (en) | 2021-07-14 | 2023-01-19 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
CN118251491A (zh) | 2021-10-28 | 2024-06-25 | 瑞泽恩制药公司 | 用于敲除C5的CRISPR/Cas相关方法及组合物 |
CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
WO2024046234A1 (zh) * | 2022-08-30 | 2024-03-07 | 天辰生物医药(苏州)有限公司 | 抗人补体c5抗体以及其融合蛋白 |
WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024054408A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024072798A1 (en) | 2022-09-28 | 2024-04-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for preventing or minimizing cardiac surgery associated acute kidney injury (csa-aki) and/or subsequent major adverse kidney events (make) in patients with chronic kidney disease |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
DE69233010T2 (de) | 1991-07-15 | 2004-02-19 | Oklahoma Medical Research Foundation, Oklahoma | Universale spenderzellen |
AU4657993A (en) | 1992-06-29 | 1994-01-24 | Alexion Pharmaceuticals, Inc. | Matrix for universal donor microvascular endothelial cells |
EP0751787B1 (en) | 1994-03-23 | 2005-01-12 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5562904A (en) | 1994-07-21 | 1996-10-08 | Alexion Pharmaceuticals, Inc. | Retroviral transduction of cells using soluble complement inhibitors |
DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
US6673346B1 (en) | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
EP2113516B1 (en) | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Antibodies against C5 inhibiting type II endothelial cell activation |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
EP1878441B1 (en) | 2001-08-17 | 2018-01-24 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US20040115194A1 (en) | 2002-09-06 | 2004-06-17 | Yi Wang | Method of treatment of asthma using antibodies to complement component C5 |
WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
AU2004242759B2 (en) | 2003-06-02 | 2009-11-26 | Volution Immuno Pharmaceuticals Sa | Complement inhibitors from ticks |
KR101076516B1 (ko) | 2003-09-08 | 2011-10-24 | 파나소닉 주식회사 | 플라즈마 처리방법 및 장치 |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
US20090028850A1 (en) | 2004-05-14 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
US7763708B2 (en) | 2004-08-12 | 2010-07-27 | Institute For Protein Science Co., Ltd. | Methods and compositions for modulating C5-a-mediated inflammatory responses |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
AU2013200223B2 (en) | 2005-11-04 | 2015-08-20 | Genentech, Inc. | Use of Complement Pathway Inhibitors to Treat Ocular Diseases |
KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
RS53864B1 (en) | 2006-03-02 | 2015-08-31 | Alexion Pharmaceuticals, Inc. | EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
ES2530428T3 (es) | 2006-09-05 | 2015-03-02 | Alexion Pharma Inc | Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
CA2662716C (en) | 2006-09-08 | 2017-11-21 | Varleigh Limited | Method of treating respiratory disorders |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
ES2545775T3 (es) | 2007-02-05 | 2015-09-15 | Apellis Pharmaceuticals, Inc. | Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio |
PE20091388A1 (es) | 2007-11-02 | 2009-09-24 | Novartis Ag | Moleculas y metodos para modular el componente de complemento |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
US8839387B2 (en) | 2009-01-28 | 2014-09-16 | Headwater Partners I Llc | Roaming services network and overlay networks |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
AU2014201433B2 (en) | 2008-08-05 | 2016-05-26 | Novartis Ag | Compositions and methods for antibodies targeting complement protein C5 |
WO2010039690A1 (en) | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
US9891219B2 (en) | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
PT2894165T (pt) | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
RU2012102021A (ru) | 2009-06-23 | 2013-07-27 | Алексион Фармасьютикалз, Инк. | Биспецифические антитела, которые связываются с белками комплемента |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
EP2454623A1 (en) | 2009-07-17 | 2012-05-23 | Corning Cable Systems LLC | Optical fiber ribbons and ribbon matrix materials having low oligomer content |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
CN102762223B (zh) | 2010-01-08 | 2014-09-03 | 沃卢申伊谬诺制药公司 | 用于治疗呼吸道病毒性感染的ev576 |
SI3095871T1 (sl) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
MX2012010116A (es) | 2010-03-01 | 2013-02-26 | Alexion Pharma Inc | Metodos y composiciones para el tratamiento de la enfermedad de degos. |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
AU2015201676B2 (en) | 2010-04-30 | 2016-10-13 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
AU2011270959A1 (en) * | 2010-06-22 | 2013-01-10 | Musc Foundation For Research Development | Antibodies to the C3d fragment of complement component 3 |
JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 視神経脊髄炎を処置するための組成物および方法 |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
US10010513B2 (en) | 2012-05-25 | 2018-07-03 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
US9133269B2 (en) | 2012-08-24 | 2015-09-15 | Anaptysbio, Inc. | Humanized antibodies directed against complement protein C5 |
TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分c5拮抗劑之篩選分析 |
EP2975055A4 (en) | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
ES2768648T3 (es) | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
KR101834469B1 (ko) | 2013-08-07 | 2018-03-06 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
JP6654137B2 (ja) | 2013-09-16 | 2020-02-26 | チルドレンズ ホスピタル メディカル センター | Hsct関連血栓性微小血管症の治療のための組成物及び方法 |
WO2015054298A1 (en) | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
US20170073754A1 (en) | 2014-02-07 | 2017-03-16 | Novartis Ag | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
SG11201606842RA (en) | 2014-02-20 | 2016-09-29 | Allergan Inc | Complement component c5 antibodies |
CA2935285A1 (en) | 2014-02-21 | 2015-08-27 | Medimmune, Llc | Anti-pcsk9-glp-1 fusions and methods for use |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
WO2015140304A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
JP6564776B2 (ja) | 2014-07-12 | 2019-08-21 | 株式会社カネカ | 複合太陽電池、太陽電池モジュール、および集光太陽電池 |
WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
LT3233921T (lt) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antikūnai ir panaudojimo būdai |
EP3247723A1 (en) | 2015-01-22 | 2017-11-29 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
EP3277715A2 (en) | 2015-03-31 | 2018-02-07 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
WO2016178980A1 (en) | 2015-05-01 | 2016-11-10 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant |
US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
US20160362482A1 (en) | 2015-06-10 | 2016-12-15 | Case Western Reserve University | Compositions and methods of modulating b cell response |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
US20180237509A1 (en) | 2015-09-28 | 2018-08-23 | Alexion Pharmaceuticals, Inc. | Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients |
WO2017062649A1 (en) | 2015-10-07 | 2017-04-13 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
US20180311345A1 (en) | 2015-10-30 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
TWI747936B (zh) | 2015-12-18 | 2021-12-01 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
MA53248A (fr) | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. | 難治性全身型重症筋無力症の処置のための方法 |
US20190225678A1 (en) | 2016-06-07 | 2019-07-25 | Novartis Ag | Anti-c5 antibody for treating patients with complement c5 polymorphism |
RU2018146778A (ru) | 2016-06-07 | 2020-07-09 | Новартис Аг | Режим дозирования антитела к c5 |
WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
IL309975A (en) | 2016-06-14 | 2024-03-01 | Regeneron Pharma | Antibodies against C5 and their uses |
UA126561C2 (uk) | 2016-06-17 | 2022-11-02 | Чугаі Сейяку Кабусікі Кайся | Застосування антитіла проти с5 |
WO2018009588A1 (en) | 2016-07-06 | 2018-01-11 | Macho Daisy Llc | Wearable device and system for personal audio messaging |
WO2018053039A1 (en) | 2016-09-14 | 2018-03-22 | The Usa, As Represented By The Secretary, Department Of Health & Human Services | Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease |
WO2018071624A1 (en) | 2016-10-12 | 2018-04-19 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
US10802945B2 (en) | 2016-12-07 | 2020-10-13 | Ab Initio Technology Llc | Differencing of executable dataflow graphs |
WO2018109588A2 (en) | 2016-12-16 | 2018-06-21 | Samsung Bioepis Co., Ltd | Stable aqueous anti-c5 antibody composition |
KR20230043247A (ko) | 2017-01-31 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
IL269122B1 (en) | 2017-03-06 | 2024-03-01 | Univ Pennsylvania | Antibodies against C5 and their uses |
JP7251792B2 (ja) | 2017-03-23 | 2023-04-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗C5a抗体とその使用 |
WO2018195034A1 (en) | 2017-04-19 | 2018-10-25 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
WO2018234118A1 (en) | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | TREATMENT OF INFLAMMATORY DISEASES BY INHIBITORS OF C5A ACTIVITY |
CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
KR20220047826A (ko) | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | 고 농도의 항-c5 제형 |
-
2017
- 2017-06-13 IL IL309975A patent/IL309975A/en unknown
- 2017-06-13 SG SG10202012243VA patent/SG10202012243VA/en unknown
- 2017-06-13 KR KR1020197001136A patent/KR102534895B1/ko active IP Right Grant
- 2017-06-13 UA UAA201900312A patent/UA124734C2/uk unknown
- 2017-06-13 MY MYPI2022000480A patent/MY196220A/en unknown
- 2017-06-13 US US15/621,689 patent/US10633434B2/en active Active
- 2017-06-13 LT LTEPPCT/US2017/037226T patent/LT3468990T/lt unknown
- 2017-06-13 MA MA045235A patent/MA45235A/fr unknown
- 2017-06-13 KR KR1020247015883A patent/KR20240070728A/ko active Search and Examination
- 2017-06-13 AU AU2017283470A patent/AU2017283470B2/en active Active
- 2017-06-13 MY MYPI2022000479A patent/MY196006A/en unknown
- 2017-06-13 WO PCT/US2017/037226 patent/WO2017218515A1/en active Application Filing
- 2017-06-13 CN CN202310681088.7A patent/CN116751293A/zh active Pending
- 2017-06-13 EP EP17731785.6A patent/EP3468990B1/en active Active
- 2017-06-13 CN CN201780049512.9A patent/CN109563159B/zh active Active
- 2017-06-13 FI FIEP17731785.6T patent/FI3468990T3/fi active
- 2017-06-13 EP EP24156366.7A patent/EP4374922A2/en active Pending
- 2017-06-13 MX MX2018015149A patent/MX2018015149A/es unknown
- 2017-06-13 KR KR1020237016626A patent/KR102667023B1/ko active IP Right Grant
- 2017-06-13 CA CA3027487A patent/CA3027487A1/en active Pending
- 2017-06-13 JP JP2018565286A patent/JP7102353B2/ja active Active
- 2017-06-13 SG SG11201810933QA patent/SG11201810933QA/en unknown
- 2017-06-13 MY MYPI2018002398A patent/MY191668A/en unknown
- 2017-06-13 CN CN202310681159.3A patent/CN116769024A/zh active Pending
- 2017-06-13 IL IL263481A patent/IL263481B2/en unknown
- 2017-06-13 DK DK17731785.6T patent/DK3468990T3/da active
-
2018
- 2018-12-05 PH PH12018502560A patent/PH12018502560A1/en unknown
- 2018-12-06 MX MX2023001726A patent/MX2023001726A/es unknown
- 2018-12-06 MX MX2023001727A patent/MX2023001727A/es unknown
- 2018-12-11 CL CL2018003563A patent/CL2018003563A1/es unknown
- 2018-12-31 CO CONC2018/0014413A patent/CO2018014413A2/es unknown
-
2020
- 2020-03-16 US US16/819,989 patent/US11479602B2/en active Active
- 2020-03-16 US US16/819,977 patent/US11492392B2/en active Active
-
2022
- 2022-05-11 JP JP2022077865A patent/JP7368543B2/ja active Active
- 2022-09-19 US US17/933,148 patent/US20230174631A1/en active Pending
-
2023
- 2023-09-11 JP JP2023146751A patent/JP2023175765A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
PH12019502275A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
PH12016502064A1 (en) | Human antibodies to middle east respiratory syndrome-coronavirus spike protein | |
MY191649A (en) | Antibodies to tigit | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MY176475A (en) | Human antibodies to pd-1 | |
JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
PH12021550255A1 (en) | Anti-npr1 antibodies and uses thereof | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
MX2018012939A (es) | Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas. | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
MX2021003636A (es) | Receptor antigenico quimerico. | |
MX2018013523A (es) | Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. | |
PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
EA201990022A1 (ru) | Антитела против c5 и их применение | |
EA202092981A1 (ru) | Антитела к l1cam и их применение | |
EA202191060A1 (ru) | Анти-npr1 антитела и их применение | |
EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |